

91. Gawin FH, Khalsa-Denison EM, Jatlow P. Flupenthixol-induced aversion to crack cocaine. *N Engl J Med* 1996; 334 (20): 1340-1
92. Gawin FH, Allen D, Humblestone B. Outpatient treatment of 'crack' cocaine smoking with flupenthixol decanoate. *Arch Gen Psychiatry* 1989; 46: 322-5
93. Khouzam HR, Mayo-Smith MF, Bernard DR, et al. Treatment of crack-cocaine-induced compulsive behavior with trazodone. *J Subst Abuse Treat* 1995; 12 (2): 85-8
94. Kosten TA, Kosten TR, Gawin FH. An open trial of sertraline for cocaine abuse. *Am J Addict* 1992; 1 (4): 349-53
95. Goldwyn DH. Cocaine abuse treated with phenelzine. *Int J Addict* 1988; 23 (9): 897-905
96. Margolin A, Avants SK, Falcioni J, et al. Preliminary investigation of selegiline for the treatment of cocaine dependence. *Am J Addict* 1996; 15 (3): 275-6
97. Margolin A, Avants SK, Kosten TR. Pemoline for the treatment of cocaine dependence in methadone-maintained patients. *J Psychoactive Drugs* 1996; 28 (3): 301-4

Correspondence and reprints: Dr *Steven Batki*, University of California, San Francisco 7M12, San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110, USA.
E-mail: batki@itsa.ucsf.edu

Erratum

Vol. 9, No. 4, page 318: Section 2.3 Drug Interactions should read: '*In vitro* studies have shown that modafinil *inhibits* isoenzyme cytochrome P450 (CYP) 2C19 activity with K_i of ≈ 39 $\mu\text{mol/L}$ (data on file, Cephalon Inc). In addition, the drug slightly induces CYP1A and CYP3A.^[41] Modafinil may therefore *decrease* the exposure of patients to drugs which are metabolised via these isoenzymes,^[41] but the clinical significance of this has yet to be established'.

[McClellan KJ, Spencer CM. Modafinil: a review of its pharmacology and clinical efficacy in the management of narcolepsy. *CNS Drugs* 1998 Apr; 9 (4): 311-324]